About Nitec Pharma
Nitec Pharma is a Healthcare company based in Reinach (Switzerland) founded in 2004, and was acquired by Horizon Therapeutics in April 2010. Circadian cytokine modulator for the treatment of rheumatoid arthritis. Nitec Pharma has raised $48 million across 2 funding rounds from investors including Deutsche Bank, Horizon Therapeutics and Atlas Venture. The company was acqui-hired. Its focus areas include Life Sciences, Immunology, Drugs and Diversified.
Company details
Nitec Pharma was established in 2004 as a spin-out from Merck KGaA and is based in Reinach, Switzerland. Operations center on the specialty pharmaceutical sector, with emphasis placed on developing and commercializing treatments for chronic inflammatory and pain-related conditions. The lead product, Lodotra, functions as a circadian cytokine modulator targeted at rheumatoid arthritis management. Focus remains on advancing such therapies through clinical and market stages.
- Headquarters Reinach, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website hugedomains.com/domain_profile.cfm
- Acquired by Horizon Therapeutics (Apr 2010)
- Total Equity Funding$48M (USD)
in 2 rounds
- Latest Funding Round$22M (USD), Series B
Oct 2008
- InvestorsDeutsche Bank
& 5 more
- Acquired byHorizon Therapeutics
(Apr 2010)
Funding Insights of Nitec Pharma
Nitec Pharma has successfully raised a total of $48M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $22 million completed in October 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $48M
- Total Rounds 2
- Last Round Series B — $22M
- First Round $26M
(Mar 2007)
- Investors Count 5
All 2 funding rounds of Nitec Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2008 | $22M | Series B | – | – | |
| Mar 2007 | $26M | Series B | – | – |
6 investors in total: 6 institutional.
Investors in Nitec Pharma
Nitec Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Deutsche Bank, Horizon Therapeutics and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
NGN Capital is engaged in venture capital investments. | ngncapital.com | New York, United States | ||
Early & late stage life sciences focused VC firm funding companies in the US and Europe | global-life-science-ventures.com | Munich, Germany | ||
Diversified banking and financial services are provided globally. | 1870 | db.com | Frankfurt Am Main, Germany | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | horizontherapeutics.com | Dublin, Ireland |
Investor details for Nitec Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nitec Pharma
4 dated milestones of Nitec Pharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Nitec Pharma is founded.
- Funding First funding round of $26.0M.
- Funding Latest funding round, Series B, of $22.0M.
- Exit Acquired by Horizon Therapeutics.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nitec Pharma
Nitec Pharma was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Nitec Pharma is headquartered in Reinach, Switzerland. It is registered at Reinach, Basel-landschaft, Switzerland.
Nitec Pharma is a funded company, having raised a total of $48M across 2 funding rounds to date. The company's 1st funding round was a Series B of $26M, raised on Mar 2007.
Nitec Pharma was established in 2004 as a spin-out from Merck KGaA and is based in Reinach, Switzerland. Operations center on the specialty pharmaceutical sector, with emphasis placed on developing and commercializing treatments for chronic inflammatory and pain-related conditions. The lead product, Lodotra, functions as a circadian cytokine modulator targeted at rheumatoid arthritis management. Focus remains on advancing such therapies through clinical and market stages.
Nitec Pharma has 6 investors. Key investors include Deutsche Bank, Horizon Therapeutics, Atlas Venture, TVM Capital Life Science, and NGN Capital.
Yes. Nitec Pharma was acquired by Horizon Therapeutics in April 2010.